This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0885066608330208v1 24/2/116    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kylasam, S. Articles by Egan, J. Search for Related Content PubMed PubMed Citation Articles by Kylasam, S. Articles by Egan, J. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Recombinat Activated Factor VII Following Pediatric Cardiac Surgery

¹ Pediatric ICU, The Children's Hospital at Westmead
² Erasmus University Rotterdam
³ Hematology Department, The Children's Hospital at Westmead
⁴ Adolph Basser Cardiac Institute, The Children's Hospital at Westmead
⁵ Pediatric ICU, The Children's Hospital at Westmead, Locked Bag 4001, Westmead 2145

^* To whom correspondence should be addressed. E-mail: jone{at}chw.edu.au.

	Abstract

Objective: Review the use of recombinant activated Factor VII following cardiac surgery. Specifically, we sought to define our current therapeutic practice indications and outcomes to assess the impact of recombinant activated factor VII on postoperative bleeding. Design: Retrospective case series. Setting: The study was conducted at the University affiliated pediatric intensive care unit. Patients and participants: All postcardiac surgical patients who received recombinant activated Factor VII between June 2002 and July 2006. Results: Cardiac surgery requiring cardiopulmonary bypass was performed on 1010 children during this period. In all, 25 (2.5%) children received recombinant activated factor VII for excessive bleeding. A single dose (180 µg/kg) of recombinant activated factor VII was given to 11 patients and 2 doses of 180 µg/kg to 14 patients. Intercostal drain losses were reduced from 12 (6.7-20.8) mL/kg/h to 3 (1-4.1) mL/kg/h, P = .018 following 1 dose of recombinant activated factor VII. In those receiving 2 doses; initial losses were 19.1 (7.5-31.7) mL/kg/h, after the first dose were 7.5 (3.6-13.7) mL/kg/h, P = .046, and after the second dose were 2 (1-2.9) mL/kg/h, P = .008. The plasma prothrombin time decreased in both the 1 dose, P = .003 and 2 dose, P = .009 groups. The activated partial thromboplastin time also decreased in the 1 dose group, P = .007 and 2 dose group, P = .03. There were no side effects attributable to recombinant activated factor VII. Annual rates of return to the operating theatre for excessive bleeding were coincidentally reduced in association with the routine use of recombinant activated factor VII from 4.3% to 1.5%, P = .019. Conclusions: Hemostasis occurred in 25 postoperative pediatric cardiac patients after recombinant activated Factor VII was given. In this setting, once conventional hemostatic therapy was optimized, recombinant activated Factor VII 180 µg/kg initially with intercostal losses greater than 10 mL/kg/h and a repeat dose after 2 hours if losses remained greater than 5 mL/kg/h was effective. No complications were found to have occurred and there was a coincidental reduction in annual returns to theatre for excessive bleeding.

First published on February 2, 2009, doi:10.1177/0885066608330208

Journal of Intensive Care Medicine 2009;24:116.

A more recent version of this article appeared on March 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?